Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
0.4518
+0.0018 (0.40%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey Meckler |
Contact Details
Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | 646 427 2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J105 |
| ISIN Number | US45339J1051 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey A. Meckler J.D. | Chief Executive Officer and Director |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
| Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | UPLOAD | Filing |
| Feb 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 12, 2025 | 8-K | Current Report |